ReviewInfection and drug resistance2020
Risk Factors of Extended-Spectrum Beta-Lactamases-Producing
Review in Infection and drug resistance, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- One Health Determinants ofInternational journal of molecular sciences · 2023Pooled it
- Antimicrobial resistance and associated risk factors in urinary tract infections diagnosed in the emergency department: a retrospective observational study.BMC infectious diseases · 2026Observational
- Article
- Prospective Evaluation of ESBL Risk Factors and Appropriateness of Empirical Therapy in Hospitalized Patients with Community-Onset Pyelonephritis.Antibiotics (Basel, Switzerland) · 2026Article
- Clinical profiles and modifiable risk factors for catheter-associated urinary tract infections in hospitalized obstetrics and gynecology patients: a case-control study.BMC infectious diseases · 2026Article
- Analysis of risk factors for urinary tract infections caused by extended spectrum β-Lactamases-producing Escherichia coli and establish the nomogram model.Urolithiasis · 2025Article
- Risk Factors Associated with Community-Onset Infections Due to Multidrug-Resistant Organisms.Antibiotics (Basel, Switzerland) · 2025Article
- Observational
- SERS-based aptasensor for culture-free detection of Escherichia coli in urinary tract infection diagnosis.Nano convergence · 2025Article
- Extended-Spectrum Beta-Lactamase Production and Carbapenem Resistance in Elderly Urinary Tract Infection Patients: A Multicenter Retrospective Study from Turkey.Antibiotics (Basel, Switzerland) · 2025Article
- Urinary Tract Infections Among Patients in Primary Healthcare Centres in Bahrain:Sultan Qaboos University medical journal · 2025Article
- Ecological and public health dimensions of ESBL-producingVeterinary world · 2025Review
- Determining the Usefulness of Selected Laboratory Markers of Inflammation in Qualifying Patients for T2 Biosystems Determination.Journal of clinical laboratory analysis · 2025Article
- Emergence of Extended spectrum β-lactamase (ESBL) and carbapenemase producingPakistan journal of medical sciences · 2025Article
- Retrospective Analysis of Antibiotic Resistance Patterns of UropathogenicHealth science reports · 2025Article
- Exploring the TEM β-Lactamase inInfection and drug resistance · 2025Article
- Genomic epidemiology of extended-spectrum beta-lactamase-producingMicrobial genomics · 2025Article
- Intersecting social and environmental determinants of multidrug-resistant urinary tract infections in East Africa beyond antibiotic use.Nature communications · 2024Article
- Association of Race or Ethnicity With Extended-Spectrum Beta-Lactamase Production inOpen forum infectious diseases · 2024Article
- Prevalence and risk factors of extended-spectrum beta-lactamase producing E. coli causing urinary tract infections in Iceland during 2012-2021.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe prevalence of extended-spectrum beta-lactamase-producing
methodsWe searched the MEDLINE, Cochrane Library, Embase and Web of Science databases without language or date restriction up to March 2019. Two independent reviewers selected studies with quantified risk factors for CA-UTI due to ESBL-EC, and assessed their quality using the Newcastle-Ottawa Scale.
resultsAmong the 5,597 studies identified, 16 observational studies (n=12,138 patients) met the eligibility criteria. The included studies were performed in various countries, and 14/16 were published after 2012. The most relevant risk factors for CA-UTI due to ESBL-EC identified were prior use of antibiotics (odds ratio (OR) from 2.2 to 21.4), previous hospitalization (OR: 1.7 to 3.9), and UTI history (OR: 1.3 to 3.8). Two risk factors were related to environmental contamination: travelling abroad, and swimming in freshwater.
conclusionOur findings could allow adapting empiric antibiotic treatments according to the patient profile. Further studies are needed to quantify the relationships between CA-UTI due to ESBL-EC and the environment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.